Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 8
Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
Received 25 January 2012
Accepted for publication 20 February 2012
Published 26 March 2012 Volume 2012:8 Pages 149—156
DOI https://doi.org/10.2147/TCRM.S17413
Review by Single anonymous peer review
Peer reviewer comments 3
Julian J Goodman, Stanley I Martin
Division of Infectious Diseases, The Ohio State University, Columbus, OH, USA
Abstract: Ceftaroline is a novel broad-spectrum cephalosporin ß-lactam antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA) as well as multidrug-resistant Streptococcus pneumoniae among other routine Gram positive and Gram negative organisms. It has been approved by the US Food and Drug Administration for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections (ABSSSIs). Ceftaroline is approved for treatment of ABSSSI due to MRSA, however currently there are no data for pneumonia due to MRSA in humans. Herein we review the major clinical trials as well as ceftaroline microbiology, pharmacokinetics, and safety, followed by a look at further directions for investigation of this new agent.
Keywords: ceftaroline, pneumonia, skin infection
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.